This trial is evaluating whether Fall Prevention Intervention will improve 2 primary outcomes and 4 secondary outcomes in patients with HIV Infections. Measurement will happen over the course of Baseline and 10 weeks (final assessment).
This trial requires 40 total participants across 2 different treatment groups
This trial involves 2 different treatments. Fall Prevention Intervention is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
HIV is a disease of people and animals. It is spread primarily through sexual activity and through a number of mother-fetal transmission methods. HIV may be transmitted via blood transfusions, organ transplants, or the reuse of contaminated medical instruments. The global spread of HIV has been a great challenge for the biomedical community. However, it is now a manageable entity for the health services to prevent, detect and treat.\n
The estimate of 636,400 new diagnoses of HIV infection is consistent with the projected 7.2 million new cases annually between 2010 and 2050. theme: psychology question: Can the clinical assessment for depression in older adults be improved by adding a self-reported questionnaire? answer: Results from a recent clinical trial of the present study suggest that the added value of a self-report questionnaire to our assessment of depression of older patients cannot be substantiated by the results obtained in this present study.
Findings from a recent study has shown that there may be a high error rate in the estimation of the cure rate of HIV in HIV-infected patients. This is due to the high loss to follow up in these studies.
HIV is an infection that most frequently is transmitted by blood transfusion, genital or injection drug injection. People of color are the most susceptible to HIV/AIDS compared to other races and socioeconomic groups.\n
Antiviral and antiretroviral medications are commonly prescribed for hiv infections but only in the short term. However, many patients continue therapy with the medication for the lifetime of the infection. In order to reduce the risk of medication misuse, hiv patients should be instructed about potential side effects of the medication.
Most current research implicates sexual behaviors as primary causes of sexually transmitted diseases (STDs). The findings of this study support the theory that STDs and HIV originated in the same population.
Falls are common occurrences in the aging community, but intervention programs do not seem to impact on injurious falls, even for high-functioning individuals. Older individuals may find many fall-prevention techniques too cumbersome (e.g. turning) to implement, even with an extensive fall-prevention education program.
We conclude that fall prevention programmes targeting both groups of patients at risk do not lead to improved mobility performance compared to patients receiving a placebo. Clinicians and researchers should continue to refine the methodology and target risk groups, and ensure an adequate assessment of mobility performance is carried out.
The intervention did not demonstrate an adequate effect in this study. The main reason may lie in the study population, which showed a lack of awareness of falls risk, and a poor level of knowledge about the intervention. The next step will be to revise the format to be used.
HIV patients are at risk of serious infections from both common viral and bacterial pathogens. Given the common nature of bacterial skin infections, we would propose that consideration of skin and ear infection as being potentially life-threatening should be added to standard HIV risk factors and clinical assessments.
Individuals infected with HIV-1 have a family history of HIV-1 disease in at least 1 member in 1 out of 10 family members with a HIV-1 infection. HIV-1 infection runs in extended family members, and this information can be useful in deciding whether to perform virological testing on family members of patients as part of HIV-1 infection screening protocols.